Explore

Trendline Trendline
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting
Trendline Trendline
Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value

Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value

Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value
Trendline Trendline
4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI-Driven Biomarkers for Cancer Treatment
Trendline Trendline
Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment
Trendline Trendline
TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment

TRIANA Biomedicines Presents TRI-611 at AACR Meeting, Highlighting Potential in Lung Cancer Treatment
Trendline Trendline
Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026
Trendline Trendline
4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate on AI Biomarkers for Cancer Treatment
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment VIR-5500

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment VIR-5500

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment VIR-5500
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Trendline Trendline
IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial
Trendline Trendline
IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma
Trendline Trendline
IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape